Apollo Hospitals Enterprise Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Apollo Hospitals reported strong Q1 FY26 results with consolidated revenue up 15% YoY to Rs. 5,842 crore, EBITDA up 26% to Rs. 852 crore, and PAT up 42% to Rs. 433 crore. Healthcare Services revenue grew 11% to Rs. 2,935 crore, Apollo HealthCo (digital and pharmacy) revenue rose 19% to Rs. 2,472 crore, and AHLL (retail health and diagnostics) revenue grew 19% to Rs. 435 crore. The Board approved a Composite Scheme of Arrangement to demerge the omni-channel pharmacy distribution and digital health business into a new entity Apollo Healthtech Limited, which has been filed with stock exchanges. The Board also approved acquiring the remaining 50% stake in Apollo Gleneagles PET-CT (AGPCL) from Parkway Healthcare for Rs. 85 million, making it a wholly owned subsidiary. Additionally, 327,494 stock options were granted to employees at Rs. 5,258 per share under the ESOP 2024 plan.
Strong quarterly performance with double-digit growth across all segments and a 42% jump in PAT signals robust operational health. The proposed demerger of the digital health and pharmacy business is aimed at unlocking shareholder value through focused capital allocation, while the AGPCL acquisition consolidates the company's diagnostic services portfolio. Investors may view these moves positively as they sharpen the business structure and improve operational efficiencies.